Nanostructured Lipid Carrier Formulations for Pulmonary Drug Delivery
Author Information
Author(s): Khan Iftikhar, Sunita, Hussein Nozad R., Omer Huner K., Elhissi Abdelbary, Houacine Chahinez, Khan Wasiq, Yousaf Sakib, Rathore Hassaan A., Fernández García Raquel, Bolás-Fernández Francisco, Fraguas-Sánchez Ana Isabel
Primary Institution: School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University
Hypothesis
This study aimed to fabricate, optimize, and characterize nanostructured lipid carriers (NLCs) loaded with trans-resveratrol (TRES) for pulmonary drug delivery.
Conclusion
Formulation F14, combined with an air-jet nebulizer, demonstrated superior stability and aerosolization performance for pulmonary drug delivery.
Supporting Evidence
- Formulation F14 showed greater stability at 4 and 25 °C for six months.
- F14 exhibited higher emitted dose (ED; 80%) and fine particle dose (FPD; 1150 µg).
- The study demonstrated that TRES-NLC formulations can effectively target the pulmonary system.
Takeaway
Researchers created a special type of tiny fat particles to deliver a medicine called trans-resveratrol to the lungs, and they found one version worked best.
Methodology
The study involved preparing 24 different formulations of TRES-NLCs using hot, high-pressure homogenization and evaluating their physicochemical properties and stability.
Limitations
The study did not specify participant demographics or clinical trials, focusing instead on laboratory formulations.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website